Ottawa, Canada
Tetra Bio-Pharma is a prominent biopharmaceutical company, founded in 2007 and headquartered in Canada. The company, listed as TSX: TBP, OTC-Pink: TBPMF, FRA: JAM1, is a leader in cannabinoid-based drug discovery and development, focusing on bringing innovative drugs and treatments to patients and healthcare providers in the biopharma, biotechnology, health care, and pharmaceutical industries.
The company recently secured a $6.00M investment in Post-IPO Debt from Alpha Blue Ocean on 11 August 2022. With this investment, Tetra Bio-Pharma aims to further advance its clinical program and expand its research and development efforts in the promising field of cannabinoid-based therapeutics.
Despite the company's promising pursuits, it's important to consider potential risks and uncertainties, as noted in Tetra Bio-Pharma's annual regulatory filing. The recent investment signifies a vote of confidence in Tetra Bio-Pharma's vision and capabilities, positioning the company for potential growth and impact in the biopharmaceutical landscape.
